In a previous clinical performance evaluation study, good concordance was shown between MammaTyper® single-marker assessments and IHC (or IHC/CISH for HER2), using 769 archived breast cancer cases available from the FinHer trial [27]. This evidence concerns the gene ERBB2 and breast cancer.